106 related articles for article (PubMed ID: 9493152)
1. Neuropsychiatric systemic lupus erythematosus before and after immunosuppressive treatment: a FDG PET study.
Otte A; Weiner SM; Hoegerle S; Wolf R; Juengling FD; Peter HH; Nitzsche EU
Lupus; 1998; 7(1):57-9. PubMed ID: 9493152
[TBL] [Abstract][Full Text] [Related]
2. Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study.
Otte A; Weiner SM; Peter HH; Mueller-Brand J; Goetze M; Moser E; Gutfleisch J; Hoegerle S; Juengling FD; Nitzsche EU
Eur J Nucl Med; 1997 Jul; 24(7):787-91. PubMed ID: 9211766
[TBL] [Abstract][Full Text] [Related]
3. Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus.
Weiner SM; Otte A; Schumacher M; Brink I; Juengling FD; Sobanksi T; Nitzsche EU; Peter HH
Lupus; 2000; 9(5):386-9. PubMed ID: 10878734
[TBL] [Abstract][Full Text] [Related]
4. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings.
Kao CH; Ho YJ; Lan JL; Changlai SP; Liao KK; Chieng PU
Arthritis Rheum; 1999 Jan; 42(1):61-8. PubMed ID: 9920015
[TBL] [Abstract][Full Text] [Related]
5. [Cerebral positron emission tomographic study in systemic lupus erythematosus].
Csépány T; Gulyás B; Trón L; Szakáll S; Kiss E; Kollár J; Sikula J; Szegedi G; Csiba L
Orv Hetil; 1997 Aug; 138(31):1947-52. PubMed ID: 9280887
[TBL] [Abstract][Full Text] [Related]
6. The role of FDG-PET, HMPAO-SPET and MRI in the detection of brain involvement in patients with systemic lupus erythematosus.
Kao CH; Lan JL; ChangLai SP; Liao KK; Yen RF; Chieng PU
Eur J Nucl Med; 1999 Feb; 26(2):129-34. PubMed ID: 9933346
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET.
Weiner SM; Otte A; Schumacher M; Klein R; Gutfleisch J; Brink I; Otto P; Nitzsche EU; Moser E; Peter HH
Ann Rheum Dis; 2000 May; 59(5):377-85. PubMed ID: 10784521
[TBL] [Abstract][Full Text] [Related]
8. Regional cerebral glucose metabolism in systemic lupus erythematosus patients with major depressive disorder.
Saito T; Tamura M; Chiba Y; Katsuse O; Suda A; Kamada A; Ikura T; Abe K; Ogawa M; Minegishi K; Yoshimi R; Kirino Y; Ihata A; Hirayasu Y
J Neurol Sci; 2017 Aug; 379():127-130. PubMed ID: 28716225
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of brain (18)F-fluorodeoxyglucose positron emission tomography in neuropsychiatric lupus patients with normal brain magnetic resonance imaging findings.
Lee SW; Park MC; Lee SK; Park YB
Lupus; 2012 Dec; 21(14):1531-7. PubMed ID: 22941565
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of the use of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography to assess the distribution of activated lymphocytes in patients with systemic lupus erythematosus.
Nowak M; Carrasquillo JA; Yarboro CH; Bacharach SL; Whatley M; Valencia X; Takada K; Brust DG; Illei GG
Arthritis Rheum; 2004 Apr; 50(4):1233-8. PubMed ID: 15077306
[TBL] [Abstract][Full Text] [Related]
11. PET/CT imaging in systemic lupus erythematosus.
Curiel R; Akin EA; Beaulieu G; DePalma L; Hashefi M
Ann N Y Acad Sci; 2011 Jun; 1228():71-80. PubMed ID: 21718325
[TBL] [Abstract][Full Text] [Related]
12. [Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].
Ampélas JF; Wattiaux MJ; Van Amerongen AP
Encephale; 2001; 27(6):588-99. PubMed ID: 11865567
[TBL] [Abstract][Full Text] [Related]
13. Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms.
Komatsu N; Kodama K; Yamanouchi N; Okada S; Noda S; Nawata Y; Takabayashi K; Iwamoto I; Saito Y; Uchida Y; Ito H; Yoshikawa K; Sato T
Eur Neurol; 1999 Jul; 42(1):41-8. PubMed ID: 10394047
[TBL] [Abstract][Full Text] [Related]
14. Resolution of neuropsychological and FDG-PET abnormalities in a patient with neuropsychiatric systemic lupus erythematosus.
Adeli A; Drubach DA; Machulda MM
Cogn Behav Neurol; 2013 Sep; 26(3):161-6. PubMed ID: 24077576
[TBL] [Abstract][Full Text] [Related]
15. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus.
Baca V; Lavalle C; García R; Catalán T; Sauceda JM; Sánchez G; Martínez I; Ramírez ML; Márquez LM; Rojas JC
J Rheumatol; 1999 Feb; 26(2):432-9. PubMed ID: 9972981
[TBL] [Abstract][Full Text] [Related]
16. Role of F-18 FDG PET-CT in neuropsychiatric systemic lupus erythematosus.
Berndorfler BD; Warwick JM; Doruyter AGG
Compr Psychiatry; 2024 Jul; 132():152480. PubMed ID: 38555700
[TBL] [Abstract][Full Text] [Related]
17. Regional specific changes of cerebral metabolism in systemic lupus erythematosus identified by positron emission tomography.
de Jong BM; Pruim J; Sinnige LG; Beintema KD; Spronk PE; Bootsma H; Kallenberg CG; van Zomeren AH; Haaxma-Reiche H
Eur Neurol; 1999; 41(4):187-93. PubMed ID: 10343148
[TBL] [Abstract][Full Text] [Related]
18. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography uptake in systemic lupus erythematosus-associated adenopathy.
Fey GL; Jolles PR; Buckley LM; Massey GV
Mol Imaging Biol; 2004; 6(1):7-11. PubMed ID: 15018823
[TBL] [Abstract][Full Text] [Related]
19. [Neuropsychiatric involvement in systemic lupus erythematosus. Part 2: diagnostic and therapy].
Weiner SM; Otte A; Uhl M; Brink I; Schumacher M; Peter HH
Med Klin (Munich); 2003 Feb; 98(2):79-90. PubMed ID: 12601532
[TBL] [Abstract][Full Text] [Related]
20. [Use of fluorodeoxyglucose PET in the diagnosis of central nervous system lupus erythematosus and a comparison with CT and MRI].
Stoppe G; Wildhagen K; Meyer GJ; Schober O
Nuklearmedizin; 1989 Oct; 28(5):187-92. PubMed ID: 2813082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
